Infectious HPIV3 was produced by the intracellular coexpression of four plasmid-borne cDNAs. These separately encoded a complete HPIV3 genome (negative-sense), the HPIV3 nucleocapsid protein N, the phosphoprotein P, and the polymerase protein L. The cDNA-encoded HPIV3 genome differed from the JS wildtype (wt) strain of HPIV3 used in its construction by seven point mutations: four of these are silent mutations in the HN or L gene coding regions that serve as markers of a cDNA-derived virus, two were introduced to create an amino acid substitution that ablates an epitope recognized by the HN-specific monoclonal neutralizing antibody 423/6, and the remaining point mutation results in an incidental amino acid substitution in the HN protein at amino acid position 263. The four plasmids were transfected into HEp-2 cell monolayers and their expression was driven by T7 RNA polymerase supplied by a vaccinia virus recombinant. The titer of virus present in the harvested transfection supernatant was low (õ5 PFU/ml), and the recovered recombinant virus (rJS) retained each of the seven mutations present in the cDNA from which it was derived. Despite the introduced and incidental mutations, rJS retained the wt phenotypes as regards replication at elevated temperature in vitro and efficient replication in the upper and lower respiratory tract of hamsters. rJS was also recovered from a cDNA encoding a complete antigenome (positivesense) with slightly greater efficiency than from the negative-sense construct. The ability to generate infectious HPIV3 from cDNA should greatly enhance our ability to develop new live-attenuated parainfluenza virus vaccines, including chimeric PIV1 and PIV2 vaccines, and to understand the genetic basis of attenuation of PIV3 candidate vaccines.
INTRODUCTION
( Karron et al., 1995a) . The cp45 virus is protective against HPIV3 challenge in experimental animals and is satisfacHuman parainfluenza virus type 3 (HPIV3) is a signifitorily attenuated, genetically stable, and immunogenic in cant cause of serious lower respiratory tract infection in seronegative human infants and children (Hall et al., infants and children less than 1 year of age (Collins et 1992; Karron et al., 1995a Karron et al., ). al., 1996 Murphy et al., 1988) . A vaccine has not been HPIV3 is a member of the paramyxovirus genus of the approved for the prevention of HPIV3 disease nor is there paramyxovirus family. Its genome is a single strand of effective antiviral therapy once disease occurs. There are negative-sense RNA that is 15,462 nucleotides (nt) in two promising live-attenuated HPIV3 vaccine candidates length (Galinski et al., 1988; Stokes et al., 1992) . It enundergoing clinical evaluation (Karron et al., 1995a,b) .
codes at least eight proteins: the nucleocapsid protein First, a bovine PIV3 (BPIV3) that is antigenically related N, the phosphoprotein P, the proteins C and D, the matrix to HPIV3 protects animals against HPIV3 infection and protein M, the fusion protein F, the hemagglutinin-neurhas been found to be safe, attenuated, genetically stable, aminidase protein HN, and the large polymerase protein and immunogenic in human infants and children (Karron L (Collins et al., 1996; Galinski, 1991; Collins, et al., 1995b, 1996) . Second, a cold-adapted HPIV3 mu-1986) . The M protein, HN protein, and F protein are assotant has been generated by 45 serial passages of the ciated with the lipid envelope. The C protein is encoded JS wildtype (wt) strain of HPIV3 in cell culture at low
by an overlapping open reading frame (ORF) of the P temperature (Belshe and Hissom, 1982) . This live-attenuprotein mRNA (Spriggs and Collins, 1986 ). ated, cold-passaged (cp) HPIV3 vaccine candidate, rePertinent to the vaccines described above, a method ferred to as cp45, exhibits the temperature-sensitive (ts), for producing virus with a wt phenotype from cDNA is cold-adaptation (ca), and attenuation (att) phenotypes needed to determine which mutation(s) in the cp45 virus specifies the ts, ca, and att phenotypes and which gene(s) of the BPIV3 specifies the attenuation phenotype.
noninfectious. The genomic RNA of negative-stranded mg/ml gentamicin sulfate, and 2 mM glutamine. The JSwt strain of HPIV3 and its attenuated ts derivative, JS cp45, viruses is tightly bound to the nucleocapsid protein N to form the ribonucleoprotein complex that, in association were propagated in LLC-MK2 cells as described previously (Hall et al., 1992) . with the phosphoprotein P, is the template for the RNAdependent RNA polymerase (large L protein) (Collins et al., 1996) . Functional nucleocapsids have been successcDNAs fully generated from the intracellular coexpression of separately transfected plasmids bearing the T7 RNA A full cDNA clone, designated p218(131) (Fig. 1A) , was constructed to encode the complete 15,462-nt genomic polymerase promoter and encoding either genomic or antigenomic RNA, and the N, P, and L proteins. The intrasequence of HPIV3 JS strain containing seven sequence markers (Fig. 1B) . A hepatitis delta virus ribozyme was cellular cDNA expression is driven by T7 RNA polymerase which is produced by coinfecting a vaccinia recombiplaced abutting the 3 end of the genomic sequence so that self-cleavage would yield the 3 end of HPIV3 (Pernant virus. This approach was first used to determine the transcription and replication requirements of cDNArotta and Been, 1991). A T7 transcription terminator was placed following the delta ribozyme. The T7 promoter encoded minireplicons (for reviews see Conzelmann, 1996; Palese et al., 1996) . The methodology has recently was placed adjacent to the 5 end of the genomic sequence such that the 5 terminal nucleotide of the HPIV3 been extended to allow the recovery of infectious rabies virus, vesicular stomatitis virus (VSV), measles virus, Sengenome was the first nucleotide synthesized. In this configuration, the cDNA encodes a complete negative-sense dai virus, and rinderpest virus from cDNA-encoded antigenomic RNA in the presence of the nucleocapsid N, copy of PIV3 genomic RNA containing the correct genomic termini without any additional heterologous nucleophosphoprotein P, and large polymerase subunit L (Baron and Barrett, 1997; Garcin et al., 1995; Kato et al., tides. A second cDNA clone designated p3/7(131) was constructed to encode the complete antigenomic se-1996; Lawson et al., 1995; Radecke et al., 1995; Schnell et al., 1994; Whelan et al., 1995) . RSV has also been quence of HPIV3 (not shown). p3/7(131) differs from p218(131) in that the positions of the T7 promoter and recovered from cDNA-encoded antigenome, but this required the transfection of an additional plasmid encoding the ribozyme/T7 terminator relative to the HPIV3 cDNA insert have been interchanged. Thus, the first nucleotide the M2 ORF 1 transcription elongation factor (Collins et al., 1995) .
synthesized in p3/7(131) is the 5 end of the antigenome, namely the positive-sense complement of genome posiWe determined in our previous work with the HPIV3 minigenome system that the N, P, and L proteins extion 1, and the 3 antigenome end defined by ribozyme cleavage is the complement of genome position 15,462. pressed from cotransfected plasmids were the minimal requirements for efficient transcription and RNA replica-A third clone designated p3/7(131)2G was constructed identical to p3/7(131) except that two G residues were tion (Durbin et al., 1997) . In this report, we describe the recovery of infectious JSwt HPIV3 from cDNA. Initially, inserted between the 5 end of the antigenome and the T7 promoter. infectious virus was recovered from cDNA encoding genomic-sense RNA. Since recovery of recombinant virus is Construction of p218(131). The HPIV3 cDNA was assembled from 14 overlapping subclones (termed A*-L) generally believed to be more efficient from antigenomic cDNA, we next constructed a cDNA encoding positiveconstructed by reverse transcription (RT) and polymerase chain reaction (PCR) of RNA isolated from virions purified sense antigenomic HPIV3 RNA. Recovery of infectious virus from this latter construct was indeed more efficient, by sucrose gradient centrifugation (Stokes et al., 1992 (Stokes et al., , 1993 . The letters in parentheses designate the individual although the difference was not great. Importantly, we demonstrate that the recovered virus manifests wt pheplasmids and do not refer to specific viral genes. The subclones spanned the following nucleotides of genomic notypes in vitro and in vivo and therefore will serve as a suitable substrate to define the attenuating mutations RNA (numbered with the 3 end being position 1): 1-2058 (A*), 1874-3111 (A), 3086-5140 (C), 4348-5276 present in its derivative, the cp45 vaccine candidate, as well as in the BPIV3 candidate vaccine virus.
(C), 5072-6695 (D*), 5904-8532 (E), 7806-9898 (F), 9632-10,740 (F), 9760-10,955 (G), 10,862-11,925 (H), 11,835-12,868 (I), 12,426-13,677 (J), 13,630-14,496 (K) , MATERIALS AND METHODS and 14, 462 (L) . Each fragment was cloned into Viruses and cells pBluescript KS II (Stratagene, La Jolla, CA) using conventional cloning techniques and was sequenced comThe modified vaccinia strain Ankara (MVA) recombinant that expresses bacteriophage T7 RNA polymerase pletely. p(L) was then subjected to site-directed mutagenesis was generously provided by Drs. L. Wyatt and B. Moss (Wyatt et al., 1995) . HEp-2 monolayer cultures were mainto introduce the T7 promoter via a single-stranded DNA intermediate according to the MUTA-GENE procedure tained at 37Њ in 5% CO 2 with OptiMEM 1 (Life Technologies, Gaithersburg, MD) supplemented with 2% FBS, 50
(Bio-Rad, Hercules, CA). The T7 promoter was positioned so that transcription initiates at the precise 5 end of the T7 promoter adjacent to nucleotide 15,462 at the 5 end of the genome. Subclones p(A*) to p(E) were assembled HPIV3 genome using the negative-sense mutagenic primer: 5-AATACGACTCACTATA*ACCAAACAAGAGAAC-3 into a second, overlapping subclone, p(A*ACCD*E), which contained HPIV3 nucleotides 1-8533. (T7 sequences are italicized, HPIV3-specific sequences are underlined, and the 5 end HPIV3 nucleotide, genome Both subclones p(E*FFGHIJKL*) and p(A*ACCD*E) were sequenced completely. In addition to the introposition 15,462, is indicated by an asterisk). This modified p(L) was designated p(L*). p(E) was modified to yield duced point mutations described above, the cDNA differed from the authentic JS HPIV3 sequence (Stokes et p(E*) by the same method using the negative-sense mutagenic oligonucleotide 5- CCAAGTACTATGAGATGCTal., 1992) by a single nucleotide substitution at position 1615, which was within the N gene and caused a substi-TCATT-3 to insert three nucleotide substitutions (underlined) into the HN gene at HPIV3 positions 7903, 7913, tution at amino acid 506 in the encoded protein. Three other nucleotide substitutions were found at positions and 7915 (Fig. 1B) . These substitutions removed an HgaI site, inserted a ScaI site, and modified amino acid 370 10,355, 11,333, and 15,248 in the L gene which did not change the encoded protein (Fig. 1B) . The last three nonof the encoded HN protein such that the epitope recognized by monoclonal antibodies (mAb) 423/6 and 170/7 coding changes were retained as additional sequence markers to identify recombinant virus (designated rJS) was ablated (van Wyke Coelingh et al., 1987) . The p(E*) to p(K) subclones were assembled in a step-wise fashion derived from cDNA, and the mutation in the N gene was corrected as described later in this paper. into the p(L*) plasmid to give p(E*FFGHIJKL*). This plasmid includes HPIV3 nucleotides 5904-15,462 with the p(A*ACCD*E) was then modified to insert the hepatitis delta virus ribozyme and T7 terminator adjacent to HPIV3 CGTAATACGACTCACTATAGGACCAAACAAGAG-3 placed the T7 promoter (boldface type) adjacent to the position 1. An HPIV3 minigenome in which the 3 end of the HPIV3 genome (GGT f GGG) (underlined) was generated 5 end of the positive-sense HPIV3 antigenome (HPIV3 sequence underlined) with two G residues inserted bethrough self-cleavage of a flanking hepatitis delta virus antigenomic ribozyme (shown in part in boldface type) was tween these two elements to improve transcription. A unique MluI site (italicized) was placed upstream of the previously constructed (Dimock and Collins, 1993; Perrotta and Been, 1991; Dimock and Collins, unpublished data) .
T7 promoter for cloning purposes. The negative-sense primer 5-1224 CGGCATCACGTGCTAC 1209 -3 spanned nt The ribozyme in turn was followed by a T7 transcription terminator. This minigenome cDNA was used as template 1209-1224 of the HPIV3 N gene and included a unique PmlI site (italicized) present in the natural HPIV3 sein a PCR which modified the sequence adjacent to the ribozyme cleavage site to be a SmaI site (CCC f GGG) and quence. Both the PCR product and the parent template p218(A*ACCD*E) were digested with MluI and PmlI and placed an ApaI site (GGGCC f C) on the downstream side of the T7 terminator. The PCR product was cloned into pKS the PCR product was then cloned into the MluI-PmlI window. A second PCR was performed using the same II which had been digested with BssHII and made bluntended by filling in with dNTPs and T4 DNA polymerase, negative-sense primer and a positive-sense primer without 2G residues inserted between the T7 promoter and yielding p218. The structure of the ribozyme was confirmed by sequencing. p218 was designed such that any sequence the 5 end of the HPIV3 antigenome. These plasmids were designated p(Left / 2G) and p(Left /). could be introduced into the opened SmaI site by blunt-end ligation and its RNA transcript would be cleaved at the p(E*FFGHIJKL*) was modified by PCR to place the delta ribozyme and T7 terminator adjacent to the 3 end of the delta ribozyme cut site (NNN f GGG). The p(A*ACCD*E) subclone was digested with HgaI and SalI (8533), releasing HPIV3 antigenome. The positive-sense primer 5-GGATTT-GCGCGC 14813 AATTTAAATCATCTGG 14828 -3 introduced a the HPIV3 cDNA, which was filled in with dNTPs and T4 DNA polymerase to give blunt termini. The HgaI site is 10
BssHII site (italicized) just upstream of a unique naturally occurring SwaI site (boldface, underlined) in the L gene of nucleotides upstream of HPIV3 position 1 and, when digested and filled in, leaves a blunt terminus beginning with HPIV3 (HPIV3 specific sequence is underlined). The negative-sense primer 5-CCCAGGTCGGACCGCGAGGAG-HPIV3 position 1. The modified HgaI-SalI fragment was gel-purified and cloned into the SmaI site of p218. The muta-GTGGAGATGCCATGCCAGCCC 15462 ACCAAAACAAGA-GAAGAACTCTGTTTGG 15435 -3 placed a portion of the delta tion in the N gene (T at nt 1615) was corrected to the JSwt sequence (A at nt 1615) (see GenBank Accession No.
ribozyme (the sequence complementary to the ribozyme is shown in boldface type) which included a naturally oc-Z11575) using Kunkel mutagenesis (Kunkel et al., 1987) . This plasmid was designated p218(A*ACCD*E).
curring unique RsrII site (italicized) adjacent to the 3 end of the HPIV3 antigenome (shown here as the negativeThe XhoI-NgoMI fragment of p(E*FFGHIJKL*), which contained the T7 promoter and the HPIV3 cDNA from sense complement, underlined). This PCR product was digested with BssHII and RsrII and cloned into the BssHIInucleotide 7438 to 15,462, was cloned into the XhoINgoMI window of p218(A*ACCD*E). This joined the RsrII window of plasmid p3/7. Plasmid p3/7 is identical to p218 except that the delta ribozyme and T7 terminator are two fragments of HPIV3 cDNA at HPIV3 nucleotide 7438, yielding a plasmid containing a full-length HPIV3 cDNA in the reverse orientation. The p3/7 plasmid containing the above-mentioned insertion was designated pPIV3-3/7 and encoding a negative-sense genomic RNA with the abovementioned three desired mutations in the HN gene and contained the complete delta ribozyme and T7 terminator adjacent to the 3 terminal 651 nucleotides of the HPIV3 three incidental mutations in the L gene. The final construct, designated p218(131), was then sequenced in its antigenome. The SwaI and NgoMI fragment of plasmid pPIV3-3/7 was then isolated and cloned into the SwaIentirety by automated sequencing at the NCI Frederick Cancer Research and Development Center (Frederick, NgoMI window of p(E*FFGHIJKL*). The resulting plasmid, designated p(Right /), placed the complete delta ribozyme MD) using the Taq Dye Deoxy Terminator Cycle Sequencing kit (ABI, Foster City, CA). This identified an and T7 terminator adjacent to the 3 end of the HPIV3 antigenome. The XhoI-NgoMI fragment of p(Right /) was additional change, namely from C to T in the HN gene at position 7593, which changed HN amino acid 263 cloned into the XhoI-NgoMI window of p(Left /) and p(Left / 2G), resulting in plasmids p3/7(131) and p3/7(131)2G, from threonine to isoleucine as indicated in Fig. 1B . This served as an additional, seventh sequence marker.
respectively. Each of these encodes the complete positivesense analog of HPIV3 antigenomic RNA, with the latter Construction of p3/7(131) 2G and p3/7(131) . The two plasmids p218(A*ACCD*E) and p(E*FFGHIJKL*) were cDNA containing two G residues adjacent to the T7 promoter for improved transcriptional efficiency. modified and joined to encode the complete positivesense antigenome of HPIV3. First, the T7 terminator and Transfection the delta ribozyme abutting the 3 end of HPIV3 in p218(A*ACCD*E) were replaced by a T7 promoter using
HEp-2 cells were grown to 90% confluence in six-well plates. Each well of a six-well plate (1.5 1 10 6 cells) was PCR. The positive-sense primer 5-GGCCCGTCGACG-transfected with the three previously described support layers on 24-well plates in serial 10-fold dilutions, allowed to adsorb for 1 hr at room temperature, overlaid plasmids (Durbin et al., 1997) 
with 1 ml of L-15 supplemented with 2 mM glutamine and 0.8% methylcellulose, and then incubated for 5 days length genomic or antigenomic HPIV3 cDNA. The plasmids were added to 0.2 ml of OptiMEM 1 (Life Technoloat the indicated temperature. The methylcellulose overlay was removed and the monolayer fixed with 80% methanol gies) containing 12 ml of LipofectACE (Life Technologies). After an incubation period of approximately 15 min at at 4Њ for 1 hr. The viral plaques present in the monolayer were immunostained with a mixture of two HPIV3-speroom temperature, 0.8 ml of OptiMEM 1 containing 2% fetal bovine serum and 1.5 1 10 7 PFU of MVA-T7 was cific anti-HN murine mAbs 101/1 and 66/4 as ascites fluid used at a dilution of 1:500, using an immunoperoxidase added to each well. The cultures were incubated at 32Њ for 12 hr, after which the medium was replaced with method specific for murine antibodies as previously described (Murphy et al., 1990) . fresh OptiMEM 1 containing 2% fetal bovine serum. The cultures were incubated at 32Њ for an additional 3 days and then the cell supernatant was harvested and pasHamster studies saged (referred to as passage 1) onto fresh HEp-2 monoGroups of nine 16-week-old golden Syrian hamsters layers. These passage 1 cultures were incubated at 32Њ
were inoculated intranasally with 0.1 ml OptiMEM 1 confor 5 days, and virus present in the cell supernatant was taining 10 5.5 PFU of rJS recovered from negative-sense harvested, passaged once in LLC-MK2 cultures, and cDNA, rJS recovered from positive-sense cDNA, JS cp45, characterized by hemagglutination-inhibition (HAI) as deor JSwt. On Day 4 postinfection, the hamsters were sacriscribed previously (van Wyke Coelingh et al., 1985) to ficed and the lungs and nasal turbinates were harvested. determine if it possessed the monoclonal antibody-resisThe lungs were homogenized in a 20% w/v L-15 suspentant mutation (MARM) that marked virus recovered from sion containing 2.5 mg/ml amphotericin B (Quality BiologcDNA. icals), 200 mg/ml pipericillin (Lederle), and 50 mg/ml gentamicin (Quality Biologicals). Similarly, the nasal turbiSequencing of recovered recombinant (designated nates were homogenized in a 10% w/v L-15 suspension.
rJS) virus
After homogenization, the samples were aliquoted and The presence of nucleotide sequence markers in the rapidly frozen in a dry-ice-ethanol bath. Virus present HN and L genes of rJS (Fig. 1B) was determined by RTin the samples was titered at a later date in 96-well plates PCR of RNA isolated from recovered virions. Virus partiof LLC-MK2 cells at 32Њ. CPE was scored at 5 and 7 days cles were precipitated from 1 ml of rJS (1 1 10 5 PFU/ml, after inoculation. The mean log 10 TCID 50 /g was calculated passage level 2) by the addition of 200 ml 25% polyethylfor each group of nine hamsters. ene glycol, incubation on ice for 1 hr, and centrifugation at 12,000 g for 15 min. The RNA was purified with TRIzol RESULTS AND DISCUSSION reagent (Life Technologies) following the manufacturer's Construction and rescue of recombinant JS strain recommended procedure. RT-PCR was performed with of HPIV3 from cDNA encoding negative-sense the Superscript kit (Life Technologies) following the mangenomic RNA (referred to as rJS-NS) ufacturer's recommended protocol. Control reactions were identical except that reverse transcriptase was A cDNA clone [p218(131)] encoding the complete geomitted from the reaction to confirm that the PCR prodnome of the HPIV3 JS strain was constructed as deucts were derived solely from viral RNA and not from scribed under Materials and Methods. p218(131) was possible contaminating cDNA plasmids. Four primer designed such that the T7 promoter was placed adjacent pairs were used to generate PCR products from nt 7334-to the 5 trailer of the HPIV3 genome and the hepatitis 8715, 9364-10,854, 10,939-15,392, and 13,623-15,392. delta virus ribozyme directly abutted the 3 leader so that The resultant PCR products were then sequenced using cleavage of the ribozyme would generate the 3 end of cycle dideoxynucleotide sequence analysis (New Enthe HPIV3 genome free of additional heterologous nuclegland Biolabs, Beverly, MA).
otides. Three mutations were introduced into the HN gene to distinguish cDNA-recovered virus from wt virus Efficiency of plaque formation of rJS at permissive (Fig. 1B) . These mutations, at nucleotides 7903, 7913, and restrictive temperatures and 7915, removed an HgaI site from the genome and introduced a proximal ScaI site. The mutations at nt 7913 The level of temperature sensitivity of replication in vitro of control viruses and rJS derived from both and 7915 also obliterated an antibody epitope recognized by the HPIV3-specific mAbs 423/6 and 170/7 and therep218(131) and p3/7(131)2G was determined at 32, 37, 39, and 40Њ in LLC-MK2 monolayer cultures as previously fore served as a marker to readily distinguish JSwt virus from rJS-NS. A fourth mutation in the HN gene at nt posidescribed with the following modifications (Hall et al., 1992) . Viruses were inoculated onto LLC-MK2 monotion 7593 (C r T) was found during sequence analysis of the completed p218 (131) -10,355, 11,333, and 15,248 , which confirmed that rJS-NS possessed each mutation (data not shown). GHIJKL*). These four mutations were left uncorrected to serve as additional markers for virus recovered from cDNA. Thus, the sequence of p218 (131) 
differed from
Construction and recovery of recombinant virus from that of wt HPIV3 strain JS at a total of seven nucleotide cDNA encoding positive-sense antigenomic RNA positions.
p218(131) and the three support plasmids pTM(N), The results described above demonstrated the successful recovery of infectious rJS from cDNA encoding pTM(P), and pTM(L) were transfected into HEp-2 cells with MVA expressing T7 RNA polymerase. A control negative-sense genomic RNA. This differs from most published reports for recovery of other nonsegmented group consisting of pTM(N), pTM(P), pTM(L), and MVA was cotransfected into HEp-2 cells without p218(131).
negative-strand RNA viruses, in which the cDNA used for virus recovery had been designed to encode positiveOn Day 4, the transfected cells were harvested, and the supernatant was passaged onto fresh HEp-2 cell monosense antigenomic RNA (Baron and Barrett, 1997; Collins et al., 1995; Conzelmann, 1996; Garcin et al., 1995 ; Lawlayers, incubated for 5 days, and passaged again for 5 days in LLC-MK2 cultures (passage 2). Virus present in son et al., 1995; Radecke et al., 1995; Whelan et al., 1995) . The recovery of infectious virus from a cDNA encoding the passage 2 harvest was further characterized by HAI. Cultures from the transfection group which received the genomic RNA had previously been reported only in the case of Sendai virus, and the efficiency of recovery was three support plasmids without the full-length genomic clone p218(131) did not yield HPIV3. The rJS-NS recovmuch lower than for cDNA encoding antigenomic RNA (Kato et al., 1996) . In other studies, the recovery of virus ered virus was confirmed to be HPIV3 since it reacted in the HAI assay with mAbs 77/5, 101/1, and 454/11, was achieved with antigenomic cDNA but not with genomic cDNA (Lawson et al., 1995; Whelan et al., 1995) . which are specific for HPIV3 (Table 1) . It was presumptively identified as being cDNA-derived because it failed One possible explanation which was suggested was that cDNA-encoded genomic RNA might anneal to mRNA proto react with mAbs 170/7 and 423/6, consistent with the MARM mutation which had been introduced into the duced by the support plasmids, resulting in inactive hybrids (Conzelmann, 1996; Lawson et al., 1995) . It also was cDNA (Table 1) .
To confirm that rJS-NS was indeed recovered from noted that T7 RNA polymerase appeared to terminate preferentially at the gene junctions of genomic RNA, percDNA, it was analyzed in parallel with wildtype JS strain HPIV3 by RT-PCR using four primer pairs flanking the haps because the oligo(U) tract of the gene-end signal resembles the natural signal for transcription termination seven inserted marker mutations. Each PCR product obtained was dependent upon the inclusion of RT, indicatby T7 RNA polymerase (Whelan et al., 1995) . Therefore, we modified the cDNA in order to create ing that each was derived from RNA and not from contaminating cDNA (data not shown). Cycle sequencing of p3/7(131), which encodes the positive-sense antigenome, and p3/7(131)2G, which is identical to p3/7(131) the four PCR products confirmed that the sequence of with the addition of two G residues between the T7 profrequently recovered from cultures transfected with p3/ 7(131)2G than from cultures transfected with p218(131). moter and the first nucleotide of the antigenome. The addition of two G residues between the T7 promoter Since each transfection harvest, including those with p218(131), yielded rJS in experiment 2, it was not possible and the first HPIV3 nucleotide is based on our previous studies with HPIV3 minireplicons which showed that the to use this method of analysis to compare the relative efficiency of generating recombinant virus. We therefore presence of the two added G residues (as opposed to zero, one, or three added G residues) was associated estimated the relative quantity of virus present in the transfection harvest by quantitating the amount of virus with the maximum levels of minireplicon replication (Durbin et al., 1997) . Thus, these two modifications would be following one passage of the transfection harvest (Table  2 ). Since each plasmid was designed to yield an identical expected to increase the efficiency of recovery of rJS, and the two cDNAs provided the opportunity to examine virus (rJS), differences in titers of the passaged virus were considered a reflection of differences in the titer of virus separately the effects of each modification.
The two antigenome cDNAs were transfected sepapresent in transfection harvest. In experiments 1 and 2, the construct with two 5 terminal G residues was the rately into cells together with the N, P, and L support plasmids, and they were infected simultaneously with most efficient in generating rJS. This indicated that the two added residues indeed increased the efficiency of the MVA-T7 recombinant virus using the procedure described above for p218(131). Infectious virus from each recovery, but the mechanism for this small increment in efficiency was not defined. These findings indicate a antigenomic cDNA was recovered and was presumptively identified as being cDNA-derived by its inability to small, but measurable, advantage of using p3/7(131)2G as substrate for future experiments designed to introduce react with mAbs 423/6 and 170/7 (not shown).
The efficiency of recovery of recombinant virus from mutations into the HPIV3 cDNA. The small advantage in recovery of recombinant virus from p3/7(131)2G might be the three full-length plasmids encoding the genomic or antigenomic HPIV3 RNAs was next studied: (i) to deterespecially needed to recover viruses that have attenuating mutations that restrict replication in vitro. Although mine whether genomic or antigenomic cDNA is more efficient at generating recombinant virus and (ii) to deter-VSV has been recovered from antigenomic cDNA which included three G residues at the 5 terminal end, the mine the effect of two extra 5 terminal G residues on the yield of recombinant viruses (Table 2) . Unfortunately, efficiency of recovery of virus from this construct was not compared with recovery from the same construct lacking it was not possible to directly titer the transfection harvest by plaque titration because residual MVA-T7 interthe extra residues (Whelan et al., 1995) . In contrast to the experience with Sendai virus and measles virus, it fered with plaque formation of rJS on LLC-MK2 monolayer cultures. Therefore, we first compared the efficiency is clear that extraviral G residues at the 5 terminal end of the antigenome are not deleterious to recovery of reof recovery of rJS from multiple independent transfections and, as seen in experiment 1, found that rJS was more combinant virus and, in fact, appear to be advantageous ( Garcin et al., 1995; Kato et al., 1996; Radecke et al., exhibited a 100-fold reduction in titer at 37Њ and failed to produce plaques at 39 or 40Њ. The sequence of JS cp45 1995). The genomic and antigenomic plasmids without two 5 terminal guanine residues appeared equally effihas been fully determined (Stokes et al., 1993) and mutations have been identified in the leader, P, M, F, HN, and cient in generating recombinant virus. This is in contrast to previous reports which have found genomic cDNA to L genes. However, it is unknown which mutation(s) is responsible for the ca, att, or ts phenotypes. Because be less efficient than antigenomic cDNA in generating recombinant virus (Kato et al., 1996; Whelan et al., 1995) .
rJS-NS and rJS-PS demonstrate the ts / phenotype like their JSwt parent, we can now introduce each of the Characterization of the level of temperature known cp45 mutations, either alone or in combination, sensitivity of rJS-NS and rJS-PS into the full-length cDNA and evaluate the level of replication of the recombinant virus at elevated temperature. Recombinant viruses derived from either positive-or The mutation(s) responsible for the ts phenotype can negative-sense cDNA were characterized by plaque be identified in this manner and, if possible, altered by assay at 32, 37, 39, and 40Њ to determine if they were mutagenesis to contain two or more nucleotide substituphenotypically similar to JSwt virus. rJS-PS and rJS-NS tions per codon to make a recombinant cp45 virus that were comparable to the JSwt virus in their level of replicais more genetically stable. tion at elevated temperatures of 39 and 40Њ (Table 3) . This indicated that neither the sequence markers nor the Replication of rJS viruses in hamsters incidental mutations acquired during cDNA construction, in particular the HN coding change at position 263, afEach recombinant virus was then administered to fected virus growth or rendered it temperature sensitive. hamsters to determine if it retained the wt phenotype of These changes also were phenotypically silent when the efficient replication in the upper and lower respiratory virus replicated in the respiratory tract of hamsters (see tracts. Table 4 illustrates that rJS-NS and rJS-PS replicate below). This is in contrast to the ts mutant JS cp45, which to the same level as JSwt in the upper and lower respiratory tract of hamsters. This is in contrast to the JS cp45 virus which is attenuated at each site. Thus, it is clear by their substitution for the corresponding sequences in
